CaseVu
Precipio Announces Participation Details For Upcoming Shareholder Conference Call
NEW HAVEN, CT, (April 26th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides details of [...]
Apr
Precipio Completes A $3M Convertible Debt Facility
Management focuses on growth opportunities NEW HAVEN, CT, (April 23rd, 2018) – Specialty cancer diagnostics company Precipio, [...]
Apr
Precipio In Strategic Partnership Discussions For Proprietary Cytogenetics Media IV-Cell
NEW HAVEN, CT, (April 18th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today it [...]
Apr
Precipio Releases Its 2017 10-K, Files A Form S-1, And Hosts Fourth Quarter And Full Year Update Call
Management to provide strategic business update to shareholders NEW HAVEN, CT, (April 17th, 2018) – Specialty [...]
Apr
Precipio Launches ICE COLD-PCR™ Research Access Program For Cancer Centers
Complimentary Precipio ICE COLD PCR™ reagents now available to advance body of research and accelerate [...]
Apr
Important JAMA Article Underscores Superiority Of Precipio’s Liquid Biopsy Core Technology
Study cites major accuracy flaws in predominant liquid biopsy platforms offered by competitors NEW HAVEN, [...]
Apr
Precipio Files Patent For Non-Invasive Cell Capture Device For Gynecological Cancer Detection
In collaboration with Yale, feminine panty liner designed to remove obstacles to early detection NEW [...]
Precipio Enters India Liquid Biopsy Market With Adoption By Leading Laboratory
CORE Diagnostics to transition to Precipio’s price competitive ICE COLD-PCR™ platform NEW HAVEN, CT, (March [...]
Mar
Precipio Restructures Capitalization Table
Investors to convert preferred shares and exercise warrants NEW HAVEN, CT, (March 22nd, 2018) – Specialty [...]
Mar
Precipio Integrates Cost Reducing And Fast Turnaround “High Resolution Melt” Into Liquid Biopsy Platform
Enhances competitive advantage as industry’s most cost effective solution NEW HAVEN, CT, (March 20th, 2018) – [...]
Mar